مباشر

FierceBiotechPassage launches strategic review and 75% layoffs after gene therapy path blocked by FDA IlluminaFinal Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC Endpoints NewsFDA search for new CBER head focused on small group of final candidates FierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China BioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drug Endpoints NewsSupreme Court restores mifepristone access by mail Clinical OMICsBiomarker of Epigenetic Aging Could Signal Depression AmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.com FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 win Samsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce Pharma NovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma FierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQvia

FierceBiotech ٤ مايو ٢٠٢٦

Mirum maps FDA path after anti-itch candidate scores ph. 2 win

Mirum Pharmaceuticals is moving toward an FDA filing after its small molecule volixibat significantly reduced severe itching in patients with a rare liver disea...

Mirum Pharmaceuticals is moving toward an FDA filing after its small molecule volixibat significantly reduced severe itching in patients with a rare liver disease.